05/31/2017 - 2:15pm

Under the acquisition, MedCart will continue to operate as it did before, but as a new business unit under Albertsons’ pharmacy team structure, with the leadership team reporting directly to Albertsons group VP pharmacy operations, Dain Rusik.

05/30/2017 - 12:51pm
India-based Cipla announced May 25 that it would be cutting its investment in its biosimilars development arm to focus on respiratory products, Reuters reported. The company has halted plans to invest $1.3 billion in building a biotechnology plant in South Africa and is on the lookout to partner with other companies on its already existing biosimilars efforts, the report said. "We are not moving away from biosimilars. However, we are not in the aim to make them at $1 a day,” Cipla CEO Umang Vohra said. (Reuters)
 
05/26/2017 - 2:09pm

 Diplomat Pharmacy will be dispensing a recently approved treatment for rheumatoid arthritis.

05/25/2017 - 11:42am

Asembia’s Asembia1 specialty pharmacy workflow platform will be integrated with QS/1’s software platform as a result of the partnership.

05/24/2017 - 1:20pm

Government agency accepted Biologics License Application to extend Opdivo’s use to patients with hepatocellular carcinoma after prior sorafenib therapy.

05/24/2017 - 11:31am

Under the law, which was signed by President Barack Obama in December 2016, the payment structure for infusion drugs under Medicare Part B changed from an average wholesale price to an average sales price.

05/24/2017 - 10:11am

“We want to be more impactful to the people we serve and continue to build up our portfolio of products,” Larry Merlo said during the UBS Healthcare Conference in New York City.

05/23/2017 - 3:46pm

According to the agency, this is the first time it has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

05/23/2017 - 9:37am

“Pharmacists need to understand what’s happening around them regarding the availability of precision medicines and their profiles,” Murray Aitken, executive director of the Quintiles IMS Institute and co-author of the report, said during the International Pharmaceutical Federation 6th Pharmaceutical Sciences World Congress.